AORTIC DISSECTION and management of aortic dissection
Bertrand OF 201111
1. EArly Discharge after Transradial
Stenting of CoronarY Arteries:
Bivalirudin to Reduce Bleeding-
The EASY-B2B Trial
Olivier F. Bertrand, MD, PhD
Associate-Professor of Medicine, Laval University
Adjunct-Professor, Department of Mechanical Engineering, McGill University
Quebec Heart-Lung Institute
TCT-2011
2. Disclosures
Research grants: Cordis, Eli-Lilly, Bristol-Myers-
Squibb, GE Healthcare, Sanofi-Aventis, Eurocor
Consultant: Cordis, Astra-Zeneca, Opsens
Research-Scholar from Quebec Foundation for
Health Research
Funding: QHLI Foundation, Laval University
Transradial Research & Education Fund
11. Objective
In patients at high risk of
bleeding and undergoing
transradial PCI, bivalirudin
has a better safety/efficacy
profile compared to heparin
12. EASY B2B-Design
Patients at high risk of non-access site bleeding: ≥
2 risk-factors: Age > 70, female, CKD, recent GI or
organ bleeding, anemia, diabetes, prior GPI/Tnk.
≃ 2500 Transradial PCI
BAIL-OUT GPI
HEPARIN BIVALIRUDIN
1ST END-POINT: DEATH, MI, URGENT
REVASCULARIZATION,
BARC BLEEDING 2,3,5 AT 30 DAYS FU
17. Conclusion:
Residual bleeding risk remains a serious issue
Bleedings risks non-associated with PCI
procedures are frequent
Strategies to reduce residual bleeding risk
remains to be defined
Benefit of bivalirudin-monotherapy compared
to heparin-monotherapy in patients at high
residual bleeding risk remains to be
demonstrated